Communiqués Initiator Pharma A/S

Actions

INIT

DK0060775872

Temps Différé Nasdaq Stockholm Autres places de cotation 09:21:32 27/06/2024			Varia. 5j.	Varia. 1 janv.
9,95 ^SEK	+1,53 %		0,00 %	+7,68 %

10/05	Initiator Pharma A/S publie ses résultats pour le premier trimestre clos le 31 mars 2024	CI
23/02	Initiator Pharma A/S publie ses résultats pour le quatrième trimestre et l'exercice clos le 31 décembre 2023	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Initiator Pharma A/S - Resolutions of the annual general meeting 2024	24/05	AQ
Initiator Pharma Q1 2024 - Focus on sealing a deal	10/05	AQ
INITIATOR PHARMA: Q1 2024 REPORT	10/05	PU
Notice to AGM in Initiator Pharma	02/05	AQ
Annual report and Remuneration report 2023 for Initiator Pharma A/S	02/05	AQ
Initiator Pharma's pudafensine preclinical pharmacology results published in the British Journal of Pharmacology	15/04	AQ
Initiator Pharma’s pudafensine preclinical pharmacology results published in the British Journal of Pharmacology	12/04	AQ
Initiator Pharma - Q4 2023 – Breathing optimism	23/02	AQ
INITIATOR PHARMA: YEAR END REPORT 2023	23/02	AQ
MAC Clinical Research converts its receivable into shares in Initiator Pharma	21/02	AQ
Initiator Pharma A/S - Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021	24/01	AQ
Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021	23/01	AQ
Initiator Pharma expands its position to a broader Sexual Health Franchise and intensifies its business development efforts	08/01	AQ
Initiator Pharma Q3 - A historical quarter	10/11	AQ
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine	07/11	AQ
Initiator Pharma - Positive Phase IIb results	10/10/23	AQ
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine	09/10/23	AQ
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine	06/10/23	AQ
Result of incentive program LTI2023 in Initiator Pharma	25/09/23	AQ
Initiator Pharma announces indication expansion, clinical drug candidates active in models of female sexual dysfunction	20/09/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Initiator Pharma A/S

Actions

INIT

DK0060775872

Communiqués

Filtres